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Aim: To formulate Diclofenac sodium extended release tablets as per the standards given for 
extended release tablets of Diclofenac sodium in USP. 
Materials and Methods: The extended release tablets of Diclofenac sodium was prepared by using 
different concentration of polymers such as hydroxyl propyl methyl cellulose sodium K4M (HPMC 
K4M) and hydroxyl propyl methyl cellulose sodium K15M (HPMC K15M). The drug polymer 
interactions were studied by using Fourier transform infrared (FT-IR) spectroscopy. The in vitro drug 
release and drug release kinetic studies of all the formulations were performed and compared with the 
marketed product Fenac SR. The optimization done by considering the factors such as drug release 
limit given as per USP standard, t50% and release exponent (‘n’ value as per Korsmeyer Peppas). 
Results and Conclusions: The FT-IR spectroscopy studies revealed that there was no interaction 
between drug and excipients. The drug release observed that it depends on the concentration and 
nature of the rate controlling polymers used. The ANOVA studies revealed that the formulations 
show significant effect in drug release. The optimization studies proved that the formulation 
containing drug, polymer (HPMC K4M) ratio of 1:1.5 (Formulation M3) is the most satisfactory 
formulation. The stability studies proved that the formulation is stable.
KEY WORDS:  Diclofenac sodium, Extended release matrix tablet, Optimization, Drug release 
kinetics.
RESUMEN
Objetivo: Formular diclofenaco sódico extendido tabletas de liberación como por las normas dadas 
para las tabletas de liberación prolongada de diclofenaco sódico en USP.
Materiales y métodos: las tabletas de liberación prolongada de sodio diclofenaco fue preparado 
utilizando diferente concentración de polímeros como sódico de celulosa de metilo hidroxilo 
propilo K4M (HPMC K4M) y sodio de celulosa de hidroxilo propil metil K15M (HPMC K15M). Las 
interacciones de polímero de drogas se estudiaron utilizando espectroscopia de (FT-IR) infrarroja 
de transformada de Fourier. La liberación de drogas in vitro y drogas liberación estudios cinéticos 
de todas las formulaciones fueron realizadas y en comparación con el producto comercializado Sor 
Fenac La optimización hecha teniendo en cuenta factores tales como límite de liberación de drogas 
dado por exponente de t50 estándar, % y liberación USP (‘ n ‘ valor como por Korsmeyer Peppas).
Resultados y conclusiones: FT-IR la espectroscopia estudios revelaron que no hubo ninguna 
interacción entre drogas y excipientes. La liberación de drogas señaló que depende de la concentración 
y naturaleza de la tasa de control de polímeros utilizados. Los ANOVA los estudios revelaron 
que las formulaciones muestran un efecto significativo en la liberación de drogas. Los estudios de 
optimización demostraron que la formulación que contiene drogas, proporción de polímero (HPMC 
K4M) de 1:1.5 (formulación M3) es la formulación más satisfactoria. Los estudios de estabilidad 
demostraron que la formulación es estable.





Pharmaceutics Research Laboratory. Nehru 







Competing interest / Conflicto de interes: 
No conflicts of interest.
Fundings / Financiación: 
Nehru college of Pharmacy, Pampay, Kerala 
was provided excellent facility for doing the 
research work.  
INTRODUCTION
The oral route is the route, most often used for 
administration of drugs. Tablets are the most popular oral 
formulations available in the market and are preferred by 
patients and physicians alike. In long-term therapy for 
the treatment of chronic disease conditions, conventional 
formulations are required to be administered in multiple 
doses and therefore have several disadvantages1. Controlled 
release (CR) tablet formulations are preferred for such 
therapy because they offer better patient compliance, 
maintain uniform drug levels, reduce dose and side effects 
and increase the safety margin for high-potency drugs2.
Oral controlled release drug delivery system that 
provides continuous release of drugs with predictable and 
reproducible kinetics for a predetermined period, either 
throughout the course of GI transit or by targeting the 
delivery of a drug near/in a specific region within the GI 
tract for either a local or systemic action1.
In controlled release drug delivery systems, drug release 
is slower than the intrinsic absorption rate; therefore drug 
release from the system becomes the apparent rate of 
absorption. If absorption is slower than distribution, a two 
compartment model collapses in to a one-compartment 
model eliminating the pronounced peak obtained with 
two-compartment model3.
In this system, a solid drug is dispersed in an insoluble 
matrix. The rate of drug release is dependent on the rate of 
drug diffusion but not on the rate of solid dissolution4.
Diclofenac sodium is a most widely used non-steroidal 
anti inflammatory drug (NSAID) used for musculoskeletal 
complaints, especially arthritis (rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis), gout attacks, and 
pain management in case of kidney stones and gallstones. 
Diclofenac sodium solubility is pH dependent and absorption 
occurs throughout the intestinal tract. Diclofenac sodium 
has biological half life of 2 h and it absorbs throughout the 
intestinal tract. The drug shows linear pharmacokinetics, is 
suitable for oral controlled release tablets and it would be 
advantageous to slow down its release in GI tract not only 
to prolong its therapeutic action but also minimize possible 
side effects of Diclofenac5.
Materials and Methods
Materials:
Diclofenac sodium obtained as a gift sample from Modern 
pharmaceutical industries Pvt Ltd. Tirur, Hydroxy Propyl 
Methyl Cellulose K4M (HPMC K4M) & Hydroxy Propyl 
Methyl Cellulose K 15 M (HPMC K15M) obtained from 
Colorcon Asia Pvt Ltd. Goa, Magnesium stearate and talc 
purchased from Karnataka Fine Chem.        
Methods:
Fourier transform infrared (FT-IR) spectroscopy: Physical 
mixtures of drug and excipients were prepared to study 
the compatibility using FT-IR spectroscopy6. 
Powder flow properties: The Angle of repose, Bulk density, 
Porosity, Carr’s index of the drug excipient mixtures for all 
the formulations were determined officially7-9.
Preparation of matrix tablet of Diclofenac sodium:  Matrix tablets 
were formulated by direct compression method using the 
formula as shown in the table 1. Diclofenac sodium, selected 
polymers were passed through #60 sieves separately and 
were blended in a mortar with a pestle for 10 min to obtain 
uniform mixing. This blended powder was lubricated 
with magnesium stearate and talc. The lubricated powder 
was compressed in to round tablets with 9 mm standard 
concave punch using rotary tablet punching machine10.
Evaluation of matrix tablets:
Physicochemical parameters: Diameter and thickness of the 
matrix tablets were determined by using screw gauge. 
Hardness and Friability were determined using Pfizer 
hardness tester and Roche Friabilator respectively7, 9.             
Determination of drug content: Five tablets were accurately 
weighed and powdered. A quantity of the powder 
equivalent to 100 mg of Diclofenac sodium was weighed 
accurately and extracted in 100 ml methanol by shaking 
for 20 min. After filtration through whatmann filter paper 
no.1 and sufficient dilution with methanol, samples were 
analyzed spectrophotometrically at 283 nm9, 11. 
In vitro drug release studies: Drug release studies were carried 
out using USP dissolution test apparatus (Apparatus 
I basket type). The dissolution medium was 900 ml of 
phosphate buffer pH 7.5. The release was performed 
at 37 ± 0.5 °C, with a rotation speed of 100 rpm.  10 ml 
samples were withdrawn at predetermined time intervals 
and replaced with fresh medium. The samples were 
filtered through whatmann filter paper and analyzed after 
appropriate dilution by UV spectrophotometer at 276.5 
nm. The in vitro drug release profile was compared with 
the marketed product Fenac SR (Company: Ranbaxy, Batch 
number: 9735448)12.
Kinetics modeling of drug dissolution profiles 
Zero order release kinetic: To study the zero order release 
kinetics the release data was fitted into the Following 
equation,
dQ/dt = K0                                                                      
Where, ’Q’ is the amount of drug release, ‘K0’ is the zero 
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Table 1: Master formula of Matrix tablet 
Ingredients/ 1 Tablet M1(mg) M2 (mg) M3(mg) M4(mg) M5(mg) M6(mg) M7(mg) M8(mg)
Diclofenac sodium 100
HPMC K4M 50 100 150 200 - - - -
HPMC K15 M - - - - 50 100 150 200
Magnesium stearate 2
Talc 3
order release rate constant and ‘t’ is the release time13.
First order release kinetic: To study the first order release 
kinetics the release rate data are fitted into the following 
equation.
dQ/dt = K1 Q                                                                       
Where, ‘Q’ is the fraction of drug release, ‘K1’ is the first 
order release rate constant and ‘t’ is the release time13.  
Higuchi release model: To study the Higuchi release model 
the release rate data are fitted into the following equation:
Q = KH t ½                                                        
Where, ‘Q’ is the fraction of drug release, ‘KH’ is the release 
rate constant and ‘t’ is the release time13.
Koresmeyer and Peppas kinetics: To study the Koresmeyer 
and Peppas release kinetics the release rate data was fitted 
in to following equation:
Mt/M∞ = KKP t n                                                    
Where, Mt/M∞ is the fraction of drug release, ‘KKP’ is the 
release rate constant and ‘t’ is the release time and ‘n’ is the 
diffusion exponent related to mechanism of drug release13.
Determination of ANOVA: The One way ANOVA of the 
matrix tablets were determined using the Graph pad prism 
software by considered the in vitro drug release profile7.
Optimization technique for Matrix tablets: The optimized 
formula of the matrix tablets of Diclofenac sodium were 
found out by considered the drug release kinetics (Zero 
order, First order, Higuchi and Peppas), t50% and the 
standard drug release range given in USP for extended 
release tablets of Diclofenac sodium. 
Stability studies: The optimized formulation was subjected to 
accelerated stability studies as per ICH (The International 
Conference of Harmonization) guidelines. The formulation 
was sealed in an aluminum foil and stored at 30 ± 2 ºC, 65 ± 
5%  RH and at 40 ± 2 ºC, 75 ± 5%  RH  for 2 months. Tablets 
were periodically removed and evaluated for physical 
characteristics, in vitro drug release14.
RESULTS AND DISCUSSION
Drug - excipient compatibility studies: The studies suggest 
that there is no incompatibility between drug and polymer. 
Spectra are shown in the figure 1.
Powder flow properties: The average values of Angle of 
Repose, Bulk Density, Tapped Density, Porosity and 
Compressibility of all the formulations were 28.39±0.31, 
0.401±0.002, 0.473±0.004, 16.42±0.23 and 16.56±0.17 
respectively. The flowability of the polymers was found to 
be good according to the flow properties. 
Physicochemical parameters: The mean values of hardness, 
friability, thickness, weight and drug content of prepared 
matrix tablets are recorded in the table 2. The results were 
found to be within the pharmacopoeial limits. 
Figure 1. FT-IR Spectra of physical mixture of drug 
and excipientes. A) FT-IR spectra of pure drug 
diclofenac sodium. B) FT-IR spectra of physical 
mixture of drug  and HPMC K4M. C) FT-IR spectra of 
physical mixture of drug  and HPMC K15M.
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In vitro dissolution studies: Release of drug from the matrix 
tablets varied according to the type and ratio of matrix-
forming polymer. The formulation containing HPMC K4M 
shows more cumulative drug release rate than HPMC 
K15M. The results of in vitro studies indicated that the 
rate and extent of drug release decreased significantly (p 
< 0.05) with an increase in polymer concentration, which 
may be attributed to increase in the density of polymer 
matrix followed by increasing diffusional path length for 
drug molecules. In comparison to HPMC K4 tablet, HPMC 
K15 tablets exhibited significant sustaining effect on drug 
release. This might be due to more viscosity and high 
molecular weight of HPMC K15 in addition to its slower 
rate of erosion and more swelling than HPMC K4. The 
formulation M1 have maximum cumulative drug release 
rate and M8 have least cumulative drug release rate in 
matrix tablets. Results are shown in the figure 2. The in 
vitro drug release from marketed product Fenac SR were 
compared and observed that the product is not following 
the USP standards for extended release tablets.
Drug release kinetic studies: The in vitro release data was 
fitted to various kinetic models like Higuchi, First order, 
Zero order and Koresmeyer Peppas. All the formulations 
are follows Higuchi release. Results are given in the table 
3. When the data were plotted according to the first-order 
equation, the formulations showed a comparatively poor 
linearity, with regression value of 0.905; whereas the 
regression value for zero order equation was 0.972, which 
indicated that drug release from optimized formulation 
(M3) was independent of drug concentration. In matrix 
tablets the n value for Peppas model was found to be in 
between 0.45 and 0.89, indicates that the drug released from 
the formulation by anomalous (non-Fickians) mechanism.
ANOVA: One way ANOVA of matrix tablets the shows all 
the formulations was significant for response drug release. 
The sum square and mean square values were 7338 and 
2446 respectively. The degree of freedom, F value and p 
value was 3, 6.492 and 0.0010 respectively. Values of p 
value less than 0.0500 indicate model terms are significant.
Optimization: In the numerical optimization techniques, 
the desirability approch was used to generate the 
optimum settings for the formulation. For the optimized 
formulation, the drug release at 2, 4, 8, 12 h, t50%, release 
exponent (n) were kept in target. The drug release target 
was kept according to the USP standards (Table 4), t50% 





























































a: All values are the mean of three readings ± SD 
Table 3: Summary of drug release kinetics of formulations
Kinetic profile of 
formulation
Korsmeyer Peppas Zero order First order Higuchi









































































R2:Correlation coefficient of different models; n: drug release exponents,K0:  zero order release rate constants, K: First order release rate constant.
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Table 4: Comparison of release profile of USP Diclofenac sodium extended release tablets 
with optimized formulation15.





Between 22% and 42%
Between 34% and 61%
Between 52% and 82%




94.90 in 12 h
as 6h and release exponent (n) as maximum value. It was 
concluded that the formulation M3 is the most satisfactory 
formulation.
Stability study: During the 2 months storage of formulation 
M3, values of all parameters like hardness, diameter, 
thickness, % drug content, friability were checked and 
found to be almost similar to the initial values. The drug 
dissolution and diffusion profile were similar to the initial 
profile. There was not any significant change in any value 
and also no changes in the physical appearance. So it can 
be said that formulation is stable. 
CONCLUSIONS
It was concluded that the optimized formulation M3 
follows the USP standards for extended release(ER) tablets 
of Diclofenac sodium (DS) and also the formulation is stable 
and reproducible. So by manufacturing the ER tablets of DS 
using formula M3 can reduce the side effects of DS, improve 
patient compliance by avoiding the multiple dosing and also 
can improve the therapeutic efficacy of the formulation. 
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